Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:14 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Rhizome — Always know what the FDA thinks Regulatory intelligence agents for pharma and medtech.
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
Product / news
8 product/news‑styled row(s); headline risk without filings (High).
Verified facts
Winter 2026 batch; agent platform for life sciences regulatory research.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
Customers · Thu, Jul 2, 04:20 PM · confidence 70%high quality
Pricing · Thu, Jul 2, 04:20 PM · confidence 70%high quality
Press · Thu, Jul 2, 04:20 PM · confidence 70%high quality
Newest first · 14 event(s)
Source: Customers
Know what the FDA thinks
Source: Pricing
Know what the FDA thinks
Source: Press
Know what the FDA thinks
Source: News
Know what the FDA thinks
Source: Blog
Know what the FDA thinks
Source: Jobs page
Know what the FDA thinks
Source: Careers page
Know what the FDA thinks
Source: About page
Know what the FDA thinks
Source: Homepage
Know what the FDA thinks
Source: News / page
Know what the FDA thinks
Winter 2026 batch; agent platform for life sciences regulatory research.
Source: wikipedia
Cited answers from terabytes of regulatory databases.
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
Know what the FDA thinks
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗9 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Know what the FDA thinks
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Cited answers from terabytes of regulatory databases.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Winter 2026 batch; agent platform for life sciences regulatory research.
Why it matters: Funding signal — Pre-Seed per this source; verify against the linked original before relying on it.
Open source ↗2 row(s)
Open roles and careers pages. Active hiring implies runway to spend and shows where the company is investing (engineering vs GTM vs ops).
Know what the FDA thinks
Why it matters: Hiring signal — open roles imply runway to spend and show where the company is investing.
Open source ↗Know what the FDA thinks
Why it matters: Hiring signal — open roles imply runway to spend and show where the company is investing.
Open source ↗1 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
Know what the FDA thinks
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.